GLAXOSMITHKLINE $51.48

down -0.99


19/6/2013 04:19 PM  |  NYSE : GSK  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
Quotes displayed are delayed by 15 minutes. Market data is provided by Telvent DTN
Get Trend Analysis Icon Get GSK Trend Analysis - it has underperformed the S&P 500 by 8%

ETF Alternatives



People viewing GSK also viewed: , , , ,

Competitors

Ticker Name Volume % Change
ACEL TAMIR BIOTECHNOLOGY 5.5K +1.50%
WPHM WINSTON PHARMACEUTICALS 20.0K +1.50%
CKGT CHINA KANGTAI CACTUS BIO 500.0 +1.11%
MLGGY MELDEX INTERNATIONAL 300.0 +1.00%
PARS PHARMOS 3.2K +0.73%
View All

GSK Stock Analysis

  1.

    Teva to Acquire MicroDose Therapeutx - Analyst Blog

    (AZN,TEVA,GSK,BIIB )
    This deal is in line with Teva's strategy of strengthening its position in the respiratory therapeutic area.
  2.

    Sanofi's Fluzone Quadrivalent Gets FDA Nod - Analyst Blog

    (SNY,AZN,NVO,GSK )
    Sanofi announced that the FDA has cleared its quadrivalent formulation of Fluzone
  3.

    Orphan Drug Status for ViroPharma's Maribavir - Analyst Blog

    (VPHM,RHHBY,GSK,SLXP )
    ViroPharma recently received "orphan drug designation" in the EU for its pipeline candidate, maribavir, for the treatment of cytomegaloviral (CMV) in patients suffering from impaired cell mediated immunity.

  4. Dynavax Down on Heplisav Delay - Analyst Blog

    (DVAX,AZN,GSK,ANIK )
    Dynavax recently suffered a setback when the US Food and Drug Administration (FDA) asked for additional safety data on its hepatitis B vaccine candidate, Heplisav
  5.

    Glaxo Reports Disappointing Tykerb Data - Analyst Blog

    (GSK,RHHBY,SNTS,SNY )
    GlaxoSmithKline announced disappointing data from a global phase III study evaluating the use of Tykerb

  6. AstraZeneca Pays Up To Patch Up Another Key Area

    (AZN,GSK,THRX,NVS,FRX )
    In buying Pearl, AstraZeneca is taking some of the risk out of its valuable COPD franchise.
  7.

    FDA Panel Positive on GSK's Avandia - Analyst Blog

    (SNTS,SNY,NVO,GSK )
    The FDA panel recently voted in favor of easing safety restrictions related to Glaxo's Avandia.
  8.

    Elan Continues To Make Baffling Strategic Decision

    (ELN,THRX,GSK,PRTA,SNY )
    Elan seems to be set on wasting the Tysabri windfall instead of returning it to shareholders
Free Reports
  1.

    View the Portfolios of the Worlds Top Investors, FREE!

    Learn from Warren Buffett, George Soros and More!
  2.

    5 Key Factors That Move The Currency Market

    Take Advantage of Boris Schlossberg & Kathy Lien’s Expertise, and Start Profiting Today!
  3.

    Get 10 Trading Lessons FREE

    Benefit from the knowledge of MarketClub co-founder Adam Hewison and our other trading experts, with this FREE series of educational emails and online content.
Marketplace
Trading Center